Vaccination programs save millions of lives each year globally. With more than 100 million children immunized each year, global immunization coverage has never been higher. Sources indicate that the worldwide market for vaccines is worth USD 41.4 Billion in 2021 and is estimated to reach USD 67.2 Billion in 2026 at a CAGR of 10.2% from 2021 to 2026. The key drivers driving the growth of this market are a high prevalence of diseases, rising government and nongovernment funding for vaccine development, increasing investments by companies, and increasing focus on immunization programs.
The economies of developing countries, for example, India is growing at a tremendous speed, and it is expected to grow 18% within the next decade to about USD 3 Billion by 2026. Emerging manufacturers play a critical role in the supply of vaccines of developing countries, particularly basic and some combination vaccines. 30% of UNICEF’s total procurement comes from emerging manufacturers. The decrease in vaccine prices can also be attributed to increased competition and higher production capacities for individual vaccines brought about by the entry of emerging market manufacturers, particularly in the underused vaccines market.
Vaccines World Summit 2024, for Developing Economies, aims to bring together key experts and decision-makers from vaccine manufacturers, governmental organizations, regulators, non-profit organizations, and solution providers together to aid in advancements in this industry with significantly higher collaboration.
Ahmed Ogwell Ouma
Sai D Prasad
Bharat Bhushan Rathi
Parthasarathy Sampath Kumar
Vaccination programs save millions of lives each year globally. With more than 100 million children immunized each year, global immunization coverage has never been higher. Sources indicate that the worldwide market for vaccines is expected to reach USD 48.03 Billion by 2021 from USD 32.24 Billion in 2016 at a CAGR of 8.3% from 2016 to 2021. The key drivers driving the growth of this market are a high prevalence of diseases, rising government and nongovernment funding for vaccine development, increasing investments by companies, and increasing focus on immunization programs. With factors such as advances in immunology, genetics, and vaccine technology as well as increased demand from population growth in emerging economies, the global vaccine market is expected to surpass an estimated USD 100 billion by 2025. The economies of developing countries, for example, India is growing at a tremendous speed, and it is expected to grow 10-15% within the next decade. Emerging manufacturers play a critical role in the supply of vaccines of developing countries, particularly basic and some combination vaccines. 30% of UNICEF’s total procurement comes from emerging manufacturers. The decrease in vaccine prices can also be attributed to increased competition and higher production capacities for individual vaccines brought about by the entry of emerging market manufacturers, particularly in the underused vaccines market. Vaccines World Summit, for developing economies, aims to bring together key experts and decision-makers from vaccine manufacturers, governmental organizations, regulators, non-profit organizations, and solution providers together to aid in advancements in this industry with significantly higher collaboration.
Leadership Panel - Exploring Partnerships in Developing & Manufacturing Vaccines in the International Sector
Futureproofing Pandemics & Creating Resilience in Developing Economies
New System Approaches in Designing Next Generation Vaccines in Developing Economies Vaccines for Emerging Infectious Diseases in Developing Economies
Clinical Trial Case Studies of Next- Gen & New Vaccines from South Asia
Effective Strategies to Produce and Manufacture Vaccines at Scale and Pace
Vaccine Tech Transfer
Cold Chain Management for Vaccines
Last Mile Distribution Challenges- Case Studies from Developing Economies
JNC CORPORATION / MR SANGHAVI & CO. We are in the business of providing Biotech, Pharma, Fine Chemicals & Academia solutions. With state of the art chromatography bulk media, resins, gels & equipment’s from the world’s best companies, we offer the best technical solutions & support. The Cellufine™ product line offers a broad range of chromatography resins for the purification of proteins, enzymes, and biomolecules. The media based on spherical cellulose beads, exhibits high chemical stability / mechanical strength, higher flux and inherently bio-compatible. Applications include protein / polysaccharide purification, endotoxin removal, and used worldwide purifying vaccines, therapeutic enzymes, and virus concentration / purification. Cellulose media have significantly lower Leachable than comparable polymeric beads. Gel Filtration, IEX, Affinity, and HIC media available for broad range of biomolecules and applications. Cellufine customizes media / ligands, bead sizes for challenging purification process. Besides growing and consolidating the business of international marketing of industrial products and chemical specialties, we undertake backward/forward integration activity to produce tailor-made value-added specialty products. “Our mission is to become a benchmark organization in this line of business by striving consistently to develop our organization, professional skills & infrastructure as to be highly effective in this competitive environment.” Mr. Rajiv Sanghavi Director JNC CORPORATION/MR SANGHAVI & CO. 28, Sarvodaya Industrial Estate, Near Paper Box, Off. Mahakali Caves road, Andheri East, Mumbai – 400093 Mobile : +91-9323990409 Email : [email protected] Website : www.mrsanghavico.com
Nanghavi is a Joint Venture between Sweden based R&D company Nanologica and an Indian family owned business by the Sanghavi family, thereby deriving the name “NANGHAVI”.
We are in the business of manufacturing Analytical, Semi Preparative and Prep HPLC columns by. Our in-house capabilities boasts of manufacturing the silica, functionalizing it, packing the HPLC column & marketing and selling them.
We have an end-to-end capability of manufacturing from the raw material of spherical silica to the HPLC columns itself, we can have complete control over quality of the end product.
The world’s first “Vial-to-Harvest” Vaccine manufacturing platform with Linear scalability & ultimate process efficiency.
With decades of developmental efforts & experience in Bioprocess Engineering, we have solved the most critical problems of adherent cell culture processing i.e. 1) Lack of process scalability 2) Efficiency in terms of time to market 3) Affordability in terms of cost reduction in manufacturing process.
At OmniBRx, we have invented a novel bioreactor technology for large-scale biologics / vaccines production and stem-cell therapy use. The technology provides 10X Scalability, 6X efficiency and up to 90% cost reduction during upstream manufacturing processing.
Our patented “CellBRx®️” single-use bioreactors technology is the first-of-its-kind bioreactor devices offering a fully automated and robust platform for vaccine manufacturing with linear scalability of up to 200L bioreactor volume accommodating 1500 m2 of surface area per single-use bioreactor. The proprietary DBR technology employs parallel discs stacked on multiple shafts and the intermingling rotational arrangement of the discs ensures efficient mixing and homogeneity throughout the cell carrier matrix.
With the integrated seed-train development protocol, the technology becomes the first ever close-circuit fully-automated Vial-to-Harvest production platform. The CellBRx bioreactors can grow cells in high densities and recover them efficiently with complete end-to-end process automation.
Pfanstiehl is the market leader of high purity, low endotoxin, low metal excipients for biologics, biosimilars, vaccines, cell culture media and injectable (liquid and lyophilized) formulations and supplies its products to nearly all leading global biopharmaceutical companies.
Pfanstiehl was founded in 1919 and currently celebrating its 103rd anniversary year in 2022. Pfanstiehl is headquartered at Waukegan, IL, USA and has diverse global technical support team across the globe in USA, Europe & APAC.
Pfanstiehl has manufactured parenteral grade excipients for more than 50 years, and Pfanstiehl’s high purity, low endotoxin and low metal excipient products are known as “best in class” due to their high characterization, performance, consistency, and quality attributes.
Pfanstiehl’s excipients are critical components in the majority of the global blockbuster biopharmaceutical drugs and vaccines including majority of the Covid -19 vaccines that were administered globally.
With over 35 years’ experience as a global contract service organization, SGS provides integrated (bio)pharmaceutical development and testing solutions including clinical research, pharmaceutical development, biologics characterization, biosafety, and quality control testing for small and large molecules, raw materials, containers and finished products.
SGS provides a comprehensive range of biosafety services such as: virology, cell and molecular biology, microbiology and TEM. Health Authorities (US FDA and the EMA), require companies to undergo safety testing demonstrating that cell banks, viral banks, raw materials, bulk harvests, and batches of clinical drug are free of bacteria, fungi, mycoplasma, viruses and other potential contaminants. SGS ensures product safety in satisfying these regulatory requirements.
Since 1998, Ami Polymer is in the business of Silicone Elastomeric products and also, other Polymeric components which ultimately provide solutions to Fluid Transfers, Sealing, and Contamination controls for Biopharma, Pharma, Medical, Laboratory, Food, Beverages, and Engineering sectors worldwide. We Are Experts in Silicone Tubing, Hoses & Single-Use Assemblies.
Ami Polymer is having ISO Class VII and ISO Class VIII Cleanroom facilities certified with ISO 9001:2015, ISO 14001:2015, ISO 45001:2018, ISO 27001:2013, ISO 13485:2016. We also have a BPOG extractables program for our products for regulatory markets worldwide.
Eppendorf – Stimulating growth. Cultivating Solutions
Efficient bioprocesses are central to the production of biopharmaceuticals, biomass, chemical building blocks, and nutritional products. Scientists from industry and academia trust Eppendorf bioprocess solutions for the cultivation of mammalian, insect, plant, and stem cells, as well as bacteria, yeasts, and fungi. Scalable systems support the upstream bioprocessing cycle from early development to scale-up to pilot-scale production, in working volumes from 65 mL to 2,400 L. Powerful hardware and software tools for process monitoring, control, and analytics, help to build process understanding and facilitate standardized process control. By utilizing the strong synergies between bioreactor technology and polymer manufacturing, Eppendorf developed a wide selection of single-use bioreactors and fermentors which complement its portfolio of glass and stainless-steel vessels. With worldwide technical and application services, clear technical documentation, and preventive maintenance services, Eppendorf ensures reliable system operation.
Since 1945, the Eppendorf brand has been synonymous with customer-oriented processes and innovative products, such as laboratory devices and consumables for liquid handling, cell handling and sample handling. Today, Eppendorf and its more than 5000 employees serve as experts and advisors, using their unique knowledge and experience to support laboratories and research institutions around the world.
Present your expertise to the key vaccines stakeholders from developing economies through a variety of available speaking packages.
Join the exhibition, and build an impressive presence among your potential clients.
Emphasize on your messages by promoting your brand alongside exhibition and thought leadership.
Engage with and build lasting connections that matter the most to your business.
Gain exclusive access to contacts of high-profile attendees through intimate networking opportunities.